The Miracle of Soy In
Eliminating Menopause Symptoms
And Providing Optimal Health!
Thursday, January 20th,
9 PM (ET), 6 PM (PT)
AARON TABOR, M.D.
Power Surge Live!
Aaron Tabor, MD is the Founder and Medical Director
Revival Soy Protein,
the #1 doctor-recommended soy product
for women who can't or prefer
not to use HRT.
Dr. Tabor, Power Surge's Soy Doctor/Expert,
will address the issues of the latest news
regarding soy for treating menopause.
Dr. Tabor oversees research involving
double-blinded, placebo-controlled studies
at leading hospitals on the benefits of soy
in the areas of
breast and prostate cancer.
Dr. Tabor will answer all your questions
for treating menopause symptoms,
the effectiveness of soy in lowering cholesterol
bones, for weight loss, vaginal dryness,
the depression and anxiety associated with menopause
and soy for
Soy is a viable option to HRT.
* FREE variety packs of Revival Soy
will be given away at the chat!
Thursday, January 20th
Power Surge Live!
Your UserName and Password from the Cushing's Chatroom
will work in this Power Surge Chatroom.
No need to re-register!
Read Dr. Tabor's last transcript
Discuss Soy and Revival Soy Protein here.
Transcripts of guest chats can be found
after the chat takes place.
Discovery Health aired Sam's show, "Mystery Diagnosis", Monday, November 15, 10PM EST. Upcoming viewings will be 1/10/05, 1/13/05, 1/16/05. This show was be the first in a series called Diseases Doctors Miss. Every year, millions of Americans fall prey to ailments that go undiagnosed or misdiagnosed. Medical professionals struggle to understand their baffling conditions. More info here »
Sam and her mom, Jackie, will answer questions in an online Guest Chat Wed. February 9, 2005, in the Cushing's Chatroom
Thomas Rebounds From
UK FORWARD CLOSE TO FULL STRENGTH
AFTER OCTOBER SURGERY
By Jerry Tipton
That diagnosis sent shockwaves through the Kentucky
basketball program last fall.
Sophomore forward Sheray Thomas had been sluggish and
easily fatigued. Relying on their athletic backgrounds, the coaches urged
him to play harder. That didn't help.
Then a medical examination revealed the reason why Thomas
got tired so quickly: A tumor was growing on his adrenal gland.
"It kind of scared me," Thomas said yesterday when asked
about his initial reaction to the diagnosis.
It scared his coaches and teammates, too.
"I got scared," Chuck Hayes said. "That's very scary. Life
and death, really."
Doctors removed the benign tumor -- which was tennis-ball
sized, Thomas said -- in a six-hour surgery in early October.
Thomas lost about 40 pounds. UK coaches considered sitting
out Thomas this season. But once his daily post-op nausea ended after about
two weeks, he began the process of getting back in good enough shape to
"I pushed myself as hard as I could," he said. "You never
realize what you have until it's gone. You want to do anything to go back
out and play."
Thomas, whose rebounding and physical play off the bench
fit an acute UK need, returned for a cameo role against Louisville on Dec.
18. His stints increased to six and 10 minutes against William & Mary and
He's now well enough to not be satisfied with anything but
the maximum playing time possible. In other words, he's like most other
When a reporter asked if he'd expect to log eight to 10
minutes against South Carolina tonight, Thomas said his expectation was
"more than that."
"I'll always say that," he added with a smile. "But that's
pretty much up to the coach."
UK Coach Tubby Smith, who earlier marveled at how quickly
Thomas got back into practice routines, said the player was now "full tilt."
Well, not quite full tilt, Smith added. With the physical
demands of practice and games, the coach expressed doubt that Thomas will
return to his playing weight of 230 pounds.
"He probably won't put that weight on until after the
season," Smith said. "But he knows how to adapt and adjust to what he has to
Thomas tried to adapt long before doctors discovered the
tumor. He recalled feeling so weak after his senior year of high school in
Upper Marlboro, Md., that he had to stay in bed for long stretches.
Thomas did not feel pain, but he noticed how quickly he
got tired. "Just from shooting before practice, before stretching," he said.
"I didn't feel ready to go. Something was taking away my energy, making me
"The coaches said I wasn't going as hard as I could. Being
lazy, pretty much."
Then Thomas learned of the tumor at the end of September.
Yes, he said, he wondered if he'd play basketball again.
"That was the thought in my head," Thomas said. "People
were saying that. I always thought I'd come back. I was scared, but I stayed
Doctors needed six hours to remove the tumor, in part,
because the adrenal gland is in the back of the abdomen and requires a
methodical surgical touch to reach, and because the tumor was large.
As difficult as the surgery was, the recovery period was
"way worse," Thomas said. "Horrible."
Thomas grew nauseous. "Every day I was sick," he said. "It
was a rough couple weeks."
The surprise of his post-op difficulties, which can be a
normal effect of major surgery, probably slowed his recovery.
"A big shock," he said. "I guess I didn't ask as many
questions (before surgery) as I needed to."
Now, Thomas said he feels good. He brushed off a bruised
knuckle on his right ring finger.
"No injury is fun," he said, rubbing the knuckle, "but
this is better than the injury I had before."
His return caused a hooray-for-Sheray reaction from
teammates and coaches.
"It's unbelievable," Patrick Sparks said. "He's made big
strides. People were talking of redshirting. It's given us an inspirational
Doctors give ‘fat’ woman new life Goes from size 24 to 8 after tumor removed
Abram Katz, Register Science Editor
Karen Kinne is two different people: "before" and "after."
Just like the retouched models in questionable diet ads, only painfully real.
From adolescence to adulthood she was oddly obese, a glutton in her own eyes with no self-control.
But the problem wasn’t diet or overeating.
Kinne grew bigger and bigger as an undiagnosed and rare hormonal disorder was dragging her toward an early death.
She was weak and sleeping 20 hours a day when physicians figured out that she had Cushing’s syndrome and a Yale surgeon intervened.
Now Kinne, 32, is a new person.
"I’m starting a new life. I feel like I’ve lost so many years to the disease. For more than half of my life I’ve had this disease," she said. "It robbed me of happiness." After a long and complex convalescence, she’s a normal weight and shape with normal blood pressure, normal skin and normal metabolism.
"I’ve been through four wardrobes since surgery: size 22-24, then size 18, size 12, then size 10-12 and now size 8," she said.
When now normal Kinne went back to work in March she was a stranger.
"People I’d worked with for 4½ years didn’t recognize me. They walked right by me in the hall," she said.
About 10 in 1 million develop Cushing’s syndrome, a devastating condition that many doctors fail to diagnose.
The disorder mimics an array of diseases because the very machinery that maintains all of the body’s work seizes and shuts down.
Specifically, a pathologically large amount of an essential hormone overwhelms the glands that normally regulate it.
It began when a small tumor formed for no known reason on Kinne’s left adrenal gland during her teens.
The adrenal gland sits atop the kidney.
The core of the gland produces adrenaline, which prepares the body to fight or flee.
The outer cortex makes cortisol at the request of the pituitary gland, which hangs from the underside of the brain.
Cortisol is a vital glucocorticoid hormone. Cortisol and other glucocorticoids affect every organ system and cell in the body, except for red blood cells.
Without it, you’re dead.
But too much throws the body’s organs wildly out of balance.
The adrenal tumor flooded Kinne’s 5-foot-3-inch body with enough cortisol for six people.
Left untreated, most people with Cushing’s syndrome die prematurely.
But before they succumb, they become obese. Weak and depressed. Easily bruised.
Blood pressure soars, insulin stops working and the immune system goes flat.
Surgeons at Yale excised the tumor in May and repaired Kinne’s sagging exterior.
But it has taken months for her hypothalamus, pituitary gland, adrenal cortex and the rest of her endocrine system to return to normal.
The array began to malfunction dramatically in her senior year of high school, in 1989.
Kinne gradually started to gain weight, mostly around her abdomen.
"I tried to hide it. I wore longer shirts," she said.
A slim 97 pounds became 150 pounds.
Her blood pressure rose.
"I had a big appetite and was always trying to diet. I felt like I was eating too much," she said.
By 2001, her weight had increased to 175 pounds. Instead of swelling into an exaggerated pear shape, the pounds kept collecting on her belly.
"I was very large. People, strangers, started to ask me, ‘When is the baby due.’"
The question was mortifying.
"From then on, I didn’t go out except to go to work," Kinne said.
Acne erupted on her normally clear skin.
Even prescription drugs had no effect.
She was now shopping for plus-size clothes.
Kinne’s hellish metamorphosis accelerated. Her face filled out and became round.
She developed a pad of fat (doctors call it a "buffalo hump") on her back at the base of her neck.
Kinne was thinking about killing herself.
Finally, her gynecologist, Dr. Vincent Pepe of Cheshire, asked Kinne what she was eating.
"He said the food didn’t account for the weight and asked me to take some tests," she said.
Kinne has six times the normal level of cortisol.
Pepe told her that she had Cushing’s syndrome and recommended an endocrinologist, Dr. Richard Kayne, also of Cheshire.
Kayne’s office wanted to see her immediately.
"That night, I looked up Cushing’s syndrome on the Web. It said there was a tumor on my pituitary or adrenal gland and that it might be cancer. I cried all night," she said.
When she met Kayne her anxiety was obvious.
"He said, ‘I see you’ve been looking up Cushing’s syndrome on the Internet,’ " she said.
Kayne referred Kinne to Dr. Robert Udelsman, chief of surgery at Yale-New Haven Hospital and one of a relatively small group of surgeons who treat Cushing’s syndrome.
Udelsman’s spacious office has one oil painting: a portrait of Dr. Harvey Cushing, who published a paper in 1912 on a new syndrome he had discovered.
Cushing spent the final years of his career at Yale, after "Cushing’s syndrome" had become part of the medical lexicon.
Udelsman said Cushing’s syndrome is most commonly caused by doctors prescribing prednisone, hydrocortisone and other steroids for a variety of ailments.
In these cases, the syndrome is mild and transient.
Otherwise, the syndrome can arise from one of four problems in the glucocorticoid system, Udelsman said.
When working normally, the hypothalamus produces corticotropin releasing hormone or CRH. The pituitary responds to CRH by making adrenocorticotropic hormone, or ACTH.
When ACTH reaches the adrenal glands, they produce cortisol. Cortisol-containing blood circulates back to the hypothalamus and pituitary, which respond by reducing production of CRH and ACTH, Udelsman said.
Cortisol ordinarily peaks at 8 a.m. and 10 p.m.
A tumor on the pituitary can generate too much cortisol. This condition is called Cushing’s disease. A tumor near the pituitary can do the same thing.
Or, as in Kinne’s case, a tumor, benign or cancerous, can form in the adrenal glands and pour out huge amounts of cortisol.
The result is obesity of the trunk, protein deprivation, increased fat, loss of menstruation, acne, reduced bone density, diabetes, increased blood pressure, a suppressed immune system, infections and other symptoms.
Untreated, Cushing’s syndrome often ends in death.
Treatment for all types of Cushing’s syndrome is surgery, Udelsman said.
Until recently, gaining access to the adrenal gland required major surgery, a large incision and a long recovery time.
Udelsman removed Kinne’s tumor laparoscopically, using narrow wandlike instruments inserted into the abdomen through several small incisions.
Kinne’s tumor was not cancerous.
However, continued exposure to cortisol left her pituitary atrophied and unable to make any ACTH.
In other words, she went from making too much cortisol to not being able to make any.
So Kinne had to be given cortisol. The extra weight stayed on for six months and then rapidly disappeared.
Finally, when her endocrine system came back, she had to be weaned off glucocorticoids, which normally induce euphoria.
Dr. Joseph H. Shin, director of plastic, reconstructive and aesthetic surgery at Yale, tightened her abdominal muscles and removed folds of remaining loose skin.
Kinne now weighs about 130 pounds.
"I’m very happy that I lost all that weight and look like a normal person," she said.
"I’m much more sympathetic to obese people. I know how difficult it is, not having control."
She’s working again as a paralegal at Travelers Life & Annuity in Hartford.
An unhappy four-year marriage officially ended at about the same time. The stress of her medical problems was too much for her former husband, she said.
Now she notices men glancing at her.
They pay more attention to the 132-pound "after" Kinne than to the 205-pound "before" version.
"It’s flattering. I’ve always been a flirt," she said.
But she hasn’t forgotten her other self.
"What bothered me the most was the weight gain and being mistaken for being pregnant," the new Karen Kinne said.
Abram Katz can be reached at email@example.com or 789-5719.
OHSU studies 'expectancy effect,' brain disorders
From Bend.com news sources
Posted: Wednesday, January 12, 2005 2:08 PM
Reference Code: PR-20501
January 12 - PORTLAND - It's a question scientists have debated for more than 50 years: Can a person's belief or expectation of overcoming an illness improve that person's overall health?
While this so-called "expectancy effect" may not necessarily influence the underlying cause of a disease, evidence suggests it can have an impact on a patient's health outcomes. A new, National Institutes of Health-funded research program at Oregon Health & Science University aims to find out why.
The Oregon Center for Complementary and Alternative Medicine in Neurological Disorders (ORCCAMIND) in the OHSU School of Medicine has received a three-year, $2.4 million grant from the NIH's National Center for Complementary and Alternative Medicine to develop "Complementary and Alternative Medicine: Expectancy and Outcomes," or CAMEO.
CAMEO's goal is to develop expectancy effect models that can be used to study cognitive and physiological changes contributing to the phenomenon, ranging from perceived self-efficacy - the belief that a person can influence his or her own health outcome - to hormonal activity and genetic changes that affect the brain's neurotransmitter systems, such as dopamine, serotonin and opioid, said Barry Oken, M.D., professor of neurology and behavioral neuroscience in the OHSU School of Medicine, and director of ORCCAMIND and CAMEO.
Researchers also hope to improve the design of clinical trials by heightening understanding of how individual differences contribute to the variability in responses to medical interventions.
Expectancy effect is considered a component of placebo effect, a long-studied medical outcome stemming from any clinically prescribed, biologically inert substance or inactive procedure for which there is no direct biological effect, including words, pills, gestures, devices and surgery. Expectancy effect is considered more broad and includes all processes and influences that may affect the brain's anticipation of a response.
"We're not talking about the patient-physician interaction, which, to some people, is considered part of placebo effect - the contact, the handholding, the bedside manners," said Oken, who wrote a chapter about placebo effect in his 2004 book, Complementary Therapies in Neurology: An Evidence-Based Approach. "We're really thinking about people's hope or expectation that they're going to get better."
One recent study, for example, showed Parkinson's disease patients who were administered a placebo experienced changes in brain chemistry similar to that caused by symptom-treating drugs levodopa annd apomorphine.
"It's really pretty remarkable," Oken said. "In Parkinson's patients, you can show dopamine release in the basal ganglia with administration" of the placebo.
CAMEO will focus on four areas: Parkinson's disease, metabolic syndromes, Alzheimer's disease and a mouse model for multiple sclerosis, Oken said. Each area is led by a two-person team that includes a conventional medicine physician and a complementary medicine practitioner. The grant allows ORCCAMIND to build on relationships it established with the National College of Naturopathic Medicine, the Oregon College of Oriental Medicine and Western States Chiropractic College in Portland.
NCCAM developmental centers, such as CAMEO, "clearly require close affiliation with CAM centers because part of the goal was to facilitate development of research infrastructure at the CAM institutions," Oken said. "So each of the four projects is linked."
Working with complementary practitioners is important because many of them have "succeeded in harnessing this effect," Oken said. "From my point of view, they have a much better handle on how to maximize this effect than conventional practitioners."
The research teams also will study factors that may contribute to clinical benefit from expectancy effect, including stress and personality traits.
One area of the brain that CAMEO will examine closely is the hypothalamic-pituitary-adrenal axis, a cluster of neuroendocrine components that includes parts of the hypothalamus, the anterior lobe of the pituitary gland, adrenal glands and hormone-transporting systems. The axis controls reactions to stress and is believed to be linked with mood disorders.
"The HPA acts as sort of a stress mediator," Oken said. "Those kinds of things might predispose a person to have a better, bigger response (to placebo) than others."
Carlo Calabrese, N.D., M.P.H., a research professor at the National College of Naturopathic Medicine and a clinical assistant professor of neurology in the OHSU School of Medicine, will serve as CAMEO's associate director.
Needle-Free Delivery Option Exclusive to Saizen(R) Available for Patients
GENEVA, Switzerland and ROCKLAND, Massachusetts, January 10
/PRNewswire-FirstCall/ -- Serono Inc., the US affiliate of Serono (virt-x:
SEO and NYSE: SRA), announced today the availability of Saizen(R) [somatropin
(rDNA origin) for injection] for use in the treatment of patients with adult
growth hormone deficiency (AGHD), following its FDA approval.
"This new indication for Saizen(R) represents the evolution of our growth
hormone portfolio and further demonstrates our commitment to the metabolic
franchise," said James Sapirstein, executive vice president of Metabolic
Endocrinology at Serono, Inc. "Patients with AGHD who are treated with
Saizen(R) therapy can use our easy-to-use drug delivery devices such as
cool.click(R), a needle-free device that is preferred by pediatric patients
and is now available for use by adults taking Saizen(R)."
Adult Growth Hormone Deficiency (AGHD) can be effectively treated with
Saizen(R). With the U.S. approval, patients who were growth hormone deficient
during childhood and have growth hormone deficiency as an adult, may continue
to use Saizen(R). In addition, adult patients who have adult onset growth
hormone deficiency either alone, or associated with multiple hormone
deficiencies, now have access to Saizen(R) and its line of devices.
Saizen(R) can be administered using a needle-free device, cool.click(R),
the only FDA approved needle-free device for the administration of growth
hormone. It can also be administered with a recently launched autoinjector
pen device, one.click(R), or by traditional needle and syringe. Serono's
portfolio of innovative devices gives patients the choice they want in growth
Patients can learn more about Saizen(R) and Serono's growth hormone
delivery devices by talking with their physician, or by calling Serono
Connections for Growth(R) toll-free at 1-800-582-7989. The full prescribing
information for Saizen(R) can be found online at http://www.seronousa.com.
About Adult Growth Hormone Deficiency (AGHD)
Growth hormone deficiency can be a significant problem for adults even
though they no longer get taller. AGHD is recognized as a specific clinical
syndrome with numerous physiological consequences, with effects on:
- Changes in body composition, including central obesity;
- Lipids in the blood;
- Muscle strength;
- Bone composition;
- Exercise capacity and energy;
- Cardiovascular risk; and
- Psychological well-being (social isolation and depression).
There are also studies indicating that patients with AGHD have an
increased risk of mortality from cardiovascular disease, possibly
attributable to their growth hormone (GH) deficiency.
GH deficiency in adults can result from a pituitary or peri-pituitary
tumor or as a direct result of the surgery/radiation used to manage these
conditions. Less commonly, GH deficiency in adults arises from a deficiency
acquired in childhood.
Saizen(R) [somatropin (rDNA origin) for injection] is a human growth
hormone produced by recombinant DNA technology. The recommended dose for
adults at the start of therapy is .005 mg/kg daily. The dosage may be
increased to not more than .01 mg/kg daily after four weeks depending upon
the patient's tolerance of treatment.
Saizen(R) is indicated for the long-term treatment of children with
growth failure due to inadequate secretion of endogenous growth hormone. It
is indicated for replacement of endogenous growth hormone in adults with
growth hormone deficiency that meets the criteria of adult onset or childhood
In patients with AGHD, the most common adverse events with associated
growth hormone therapy are joint and muscle pain, edema, carpal tunnel
syndrome, and tingling.
Growth hormone should be used with caution in patients with insulin
resistance, glucose intolerance, diabetes, hypothyroidism, intracranial
hypertension, and in women who are pregnant or nursing. GH should not be used
in patients with Prader-Willi syndrome who are severely obese or have severe
respiratory impairment; in the presence of active neoplasia; and in patients
with proliferative or preproliferative diabetic retinopathy; or in patients
hospitalized with acute critical illnesses.
Full prescribing information for Saizen(R), including important safety
information, is available at http://www.seronousa.com.
Your Cholesterol: What Do the Numbers Mean?
By Judy Foreman
QUESTION: If your cholesterol and HDL are really good, do you need to worry about LDL?
ANSWER: Probably not, but it depends.
When doctors do a cholesterol blood test, they're looking for your low-density lipoprotein, or LDL cholesterol; your high-density lipoprotein, or HDL; and your triglycerides, or fatty acids in the blood. LDL is considered the "bad" cholesterol because it gets deposited in blood vessel walls as plaque; HDL is "good" because it take cholesterol out of the blood.
Your total cholesterol score is the sum of LDL, HDL and very low-density lipoprotein, or VLDL, which is computed by taking your triglycerides and dividing by 5.
In people without heart disease and at low or ordinary risk for it, total cholesterol should be 200 milligrams per deciliter or less, according to guidelines issued by cholesterol experts several years ago. LDL should be 130 or less. In those with heart disease or at very high risk, LDL should be less than 100 and, "better still, under 70,'' said Dr. Daniel Levy, director of the National Heart Lung and Blood Institute Framingham Heart Study.
HDL should be above 40. Triglycerides should be 150 or lower. So, if your total cholesterol were, say, 208 and your HDL were 100, by mathematics alone, that suggests your LDL is admirably low, said Dr. Zoran Nedeljkovic, an interventional cardiologist at Boston Medical Center.
Still, to assess your overall risk of heart disease, doctors also need to know your age, sex, smoking history, blood pressure, family history of heart disease, whether you have diabetes, and how much you exercise. In general, if either your total cholesterol or your LDL is higher than desirable, you can try losing weight and controlling fat intake. If that doesn't work well enough, doctors often prescribe statin drugs.
Judy Foreman is an affiliated scholar at the Women's Studies Research Center at Brandeis University.
(C) 2004, Judy Foreman. Distributed by Tribune Media Services
Endocrine Dysfunction Common After Subarachnoid
NEW YORK (Reuters Health) Dec 30 -Case reports and
evidence from small series have suggested that aneurysmal subarachnoid
hemorrhage might be associated with neuroendocrine dysfunction.
In the December issue of Stroke, Greek researchers
now report that in a larger population with long-term follow-up,
endocrine abnormalities are indeed common in patients who survive
Dr. Ioanna Dimopoulou and colleagues at the National
& Kapodistrian University of Athens performed endocrine assessments in
30 patients who had suffered aneurysmal subarachnoid hemorrhage
between 12 and 24 months earlier.
The investigators report that 14 of the 30 patients
had isolated or combined abnormalities. These included low
insulin-like growth factor 1 levels compatible with growth hormone
deficiency in 37%, hypogonadism in 13%, cortisol hyporesponsiveness to
the low-dose corticotropin stimulation test in 10% and subclinical
hypothyroidism in 7%.
The presence of endocrine abnormalities was not
correlated either with severity of the hemorrhage or with functional
outcome. In fact, the authors note that long-term functional
evaluations showed that most patients "had mainly recovered."
They point out, however, that follow-up studies of
subarachnoid hemorrhage survivors generally report relatively high
rates of functional limitations and other problems, even in patients
with good neurological recovery.
Thus the team concludes that given the high rate
endocrine dysfunction, in particular, growth hormone and gonadal
abnormalities, "screening of pituitary function is recommended in
patients surviving subarachnoid hemorrhage."
Stroke 2004; 35:2884-2889.
Centerwatch Trial Notification Service
1) Osteoporosis Research Study. This study is being conducted in:
- Tacoma, WA (http://www.centerwatch.com/patient/studies/stu67678.html)
2) What's your New Year's resolution? If your goal is to shed those
extra pounds, Research Testing Labs can help.. This study is being conducted in:
- Great Neck, NY (http://www.centerwatch.com/patient/studies/stu67718.html)
- Huntington, NY (http://www.centerwatch.com/patient/studies/stu67717.html)
3) A Research Study for High Cholesterol. This study is being conducted
- Renton, WA (http://www.centerwatch.com/patient/studies/stu67656.html)
4) Cholesterol Research Study. This study is being conducted in:
- Santa Rosa, CA (http://www.centerwatch.com/patient/studies/stu67676.html)
Additional educational resources that may be of interest to you:
Informed Consent: A Guide to the Risks and Benefits of Volunteering for Clinical
Volunteering for a Clinical Trial, a brief educational pamphlet. If you would
like to order this pamphlet click here: http://www.centerwatch.com/bookstore/pubs_cons_brochureform.html
We welcome your articles, letters to the editor, bios and
Cushing's information. Submit a Story or Article to
either the snailmail CUSH Newsletter or to an upcoming email
|To add or edit
please click here »
Lee has a 7mm pituitary tumor and an empty sella
Maudiellen had her left adrenal gland
removed laproscopically at the Cleveland Clinic on October 20, 2004.
North Canton, Ohio
Meredith has had symptoms since she was
5. She had pituitary surgery when she was 18.
Santa Rosa, California
Updated. Pat G
is one year past pituitary surgery.
She added a picture.
(close to Los Angeles area)
Rachel is not yet diagnosed
Richard has a pituitary tumor and is
Sarah had pituitary surgery in March
2003 and thought it was all over. Now she finds she still has a bit that
can't be removed by surgery and so will have radiation soon.
been told she has been living
with Cushing's for 10-15 years.
Beachwood New Jersey
Susan S had a bilateral adrenalectomy in 1976. In 1986 she
had a Pituitary tumor removed.
• If you've been diagnosed with Cushing's, please
participate in the
Cushing's Register »
The information you provide will be used to create a register
and will be shared with the medical world. It would not be used
for other purposes without your expressed permission. Note:
This information will not be sold or shared with other
Lynne Clemens, Secretary of
CUSH Org is be the
person responsible for the creation of this register. If you
have any questions you may contact her at
do not have to be a member of CUSH to fill out this
questionnaire, as long as you are a Cushing’s patient. We do not
believe that the world has an accurate accounting of Cushing’s
patients. The only way to authenticate accuracy is with actual
numbers. Your help will be appreciated. Thank you."